Acute treatment of migraine with zolmitriptan 5mg orally disintegrating tablet

Egilius L H Spierings, Alan M. Rapoport, David William Dodick, Bruce Charlesworth

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objective: To determine the speed of onset of headache response and duration of response with zolmitriptan 5mg orally disintegrating tablet (ODT) in the acute treatment of migraine. Background: Rapid pain relief is important for migraine sufferers. The early efficacy (30 minutes) of the 5mg dose of the zolmitriptan ODT formulation was evaluated. Methods: In this double-blind, parallel-group trial, 670 patients were randomised to receive either zolmitriptan 5mg ODT (n = 329) or matching placebo (n = 341) to treat two migraine headaches of moderate or severe intensity, Results: Zolmitriptan 5mg ODT was significantly more effective than placebo in achieving a headache response (reduction in migraine headache intensity from moderate or severe to mild or no pain) at 30 minutes (16.5% vs 12.5%; p = 0.048; primary endpoint), 1 hour (p < 0.0001), and 2 hours (p < 0.0001). Significantly more patients achieved a sustained headache response for 24 hours with zolmitriptan 5mg ODT than with placebo (42.5% vs 16.4%; p < 0.0001). Zolmitriptan 5mg ODT also produced a higher pain-free rate than placebo at all timepoints (0.5, 1 and 2 hours post-dose), with the differences becoming significant at 1 hour. Adverse events were reported by 37.7% of the patients treated with zolmitriptan 5mg ODT and 18.1% of the patients treated with placebo. Those that occurred most often for the patients treated with zolmitriptan 5mg ODT were tightness (7.0%), dizziness (6.7%), somnolence (6.7%) and paraesthesias (6.1%). Conclusions: A significant headache response as early as 30 minutes post-dose and good maintenance of this headache response at 24 hours makes zolmitriptan 5mg ODT an excellent acute treatment for migraine. Together with the relatively low adverse event rate, these data demonstrate that zolmitriptan 5mg ODT is a valuable therapy for migraine sufferers.

Original languageEnglish (US)
Pages (from-to)1133-1141
Number of pages9
JournalCNS Drugs
Volume18
Issue number15
DOIs
StatePublished - 2004

Fingerprint

zolmitriptan
Migraine Disorders
Tablets
Headache
Placebos
Therapeutics
Pain

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Neuropsychology and Physiological Psychology
  • Pharmacology

Cite this

Acute treatment of migraine with zolmitriptan 5mg orally disintegrating tablet. / Spierings, Egilius L H; Rapoport, Alan M.; Dodick, David William; Charlesworth, Bruce.

In: CNS Drugs, Vol. 18, No. 15, 2004, p. 1133-1141.

Research output: Contribution to journalArticle

Spierings, Egilius L H ; Rapoport, Alan M. ; Dodick, David William ; Charlesworth, Bruce. / Acute treatment of migraine with zolmitriptan 5mg orally disintegrating tablet. In: CNS Drugs. 2004 ; Vol. 18, No. 15. pp. 1133-1141.
@article{48eaa934f1584ff3b70e67ba98c08d98,
title = "Acute treatment of migraine with zolmitriptan 5mg orally disintegrating tablet",
abstract = "Objective: To determine the speed of onset of headache response and duration of response with zolmitriptan 5mg orally disintegrating tablet (ODT) in the acute treatment of migraine. Background: Rapid pain relief is important for migraine sufferers. The early efficacy (30 minutes) of the 5mg dose of the zolmitriptan ODT formulation was evaluated. Methods: In this double-blind, parallel-group trial, 670 patients were randomised to receive either zolmitriptan 5mg ODT (n = 329) or matching placebo (n = 341) to treat two migraine headaches of moderate or severe intensity, Results: Zolmitriptan 5mg ODT was significantly more effective than placebo in achieving a headache response (reduction in migraine headache intensity from moderate or severe to mild or no pain) at 30 minutes (16.5{\%} vs 12.5{\%}; p = 0.048; primary endpoint), 1 hour (p < 0.0001), and 2 hours (p < 0.0001). Significantly more patients achieved a sustained headache response for 24 hours with zolmitriptan 5mg ODT than with placebo (42.5{\%} vs 16.4{\%}; p < 0.0001). Zolmitriptan 5mg ODT also produced a higher pain-free rate than placebo at all timepoints (0.5, 1 and 2 hours post-dose), with the differences becoming significant at 1 hour. Adverse events were reported by 37.7{\%} of the patients treated with zolmitriptan 5mg ODT and 18.1{\%} of the patients treated with placebo. Those that occurred most often for the patients treated with zolmitriptan 5mg ODT were tightness (7.0{\%}), dizziness (6.7{\%}), somnolence (6.7{\%}) and paraesthesias (6.1{\%}). Conclusions: A significant headache response as early as 30 minutes post-dose and good maintenance of this headache response at 24 hours makes zolmitriptan 5mg ODT an excellent acute treatment for migraine. Together with the relatively low adverse event rate, these data demonstrate that zolmitriptan 5mg ODT is a valuable therapy for migraine sufferers.",
author = "Spierings, {Egilius L H} and Rapoport, {Alan M.} and Dodick, {David William} and Bruce Charlesworth",
year = "2004",
doi = "10.2165/00023210-200418150-00007",
language = "English (US)",
volume = "18",
pages = "1133--1141",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "15",

}

TY - JOUR

T1 - Acute treatment of migraine with zolmitriptan 5mg orally disintegrating tablet

AU - Spierings, Egilius L H

AU - Rapoport, Alan M.

AU - Dodick, David William

AU - Charlesworth, Bruce

PY - 2004

Y1 - 2004

N2 - Objective: To determine the speed of onset of headache response and duration of response with zolmitriptan 5mg orally disintegrating tablet (ODT) in the acute treatment of migraine. Background: Rapid pain relief is important for migraine sufferers. The early efficacy (30 minutes) of the 5mg dose of the zolmitriptan ODT formulation was evaluated. Methods: In this double-blind, parallel-group trial, 670 patients were randomised to receive either zolmitriptan 5mg ODT (n = 329) or matching placebo (n = 341) to treat two migraine headaches of moderate or severe intensity, Results: Zolmitriptan 5mg ODT was significantly more effective than placebo in achieving a headache response (reduction in migraine headache intensity from moderate or severe to mild or no pain) at 30 minutes (16.5% vs 12.5%; p = 0.048; primary endpoint), 1 hour (p < 0.0001), and 2 hours (p < 0.0001). Significantly more patients achieved a sustained headache response for 24 hours with zolmitriptan 5mg ODT than with placebo (42.5% vs 16.4%; p < 0.0001). Zolmitriptan 5mg ODT also produced a higher pain-free rate than placebo at all timepoints (0.5, 1 and 2 hours post-dose), with the differences becoming significant at 1 hour. Adverse events were reported by 37.7% of the patients treated with zolmitriptan 5mg ODT and 18.1% of the patients treated with placebo. Those that occurred most often for the patients treated with zolmitriptan 5mg ODT were tightness (7.0%), dizziness (6.7%), somnolence (6.7%) and paraesthesias (6.1%). Conclusions: A significant headache response as early as 30 minutes post-dose and good maintenance of this headache response at 24 hours makes zolmitriptan 5mg ODT an excellent acute treatment for migraine. Together with the relatively low adverse event rate, these data demonstrate that zolmitriptan 5mg ODT is a valuable therapy for migraine sufferers.

AB - Objective: To determine the speed of onset of headache response and duration of response with zolmitriptan 5mg orally disintegrating tablet (ODT) in the acute treatment of migraine. Background: Rapid pain relief is important for migraine sufferers. The early efficacy (30 minutes) of the 5mg dose of the zolmitriptan ODT formulation was evaluated. Methods: In this double-blind, parallel-group trial, 670 patients were randomised to receive either zolmitriptan 5mg ODT (n = 329) or matching placebo (n = 341) to treat two migraine headaches of moderate or severe intensity, Results: Zolmitriptan 5mg ODT was significantly more effective than placebo in achieving a headache response (reduction in migraine headache intensity from moderate or severe to mild or no pain) at 30 minutes (16.5% vs 12.5%; p = 0.048; primary endpoint), 1 hour (p < 0.0001), and 2 hours (p < 0.0001). Significantly more patients achieved a sustained headache response for 24 hours with zolmitriptan 5mg ODT than with placebo (42.5% vs 16.4%; p < 0.0001). Zolmitriptan 5mg ODT also produced a higher pain-free rate than placebo at all timepoints (0.5, 1 and 2 hours post-dose), with the differences becoming significant at 1 hour. Adverse events were reported by 37.7% of the patients treated with zolmitriptan 5mg ODT and 18.1% of the patients treated with placebo. Those that occurred most often for the patients treated with zolmitriptan 5mg ODT were tightness (7.0%), dizziness (6.7%), somnolence (6.7%) and paraesthesias (6.1%). Conclusions: A significant headache response as early as 30 minutes post-dose and good maintenance of this headache response at 24 hours makes zolmitriptan 5mg ODT an excellent acute treatment for migraine. Together with the relatively low adverse event rate, these data demonstrate that zolmitriptan 5mg ODT is a valuable therapy for migraine sufferers.

UR - http://www.scopus.com/inward/record.url?scp=10844221551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10844221551&partnerID=8YFLogxK

U2 - 10.2165/00023210-200418150-00007

DO - 10.2165/00023210-200418150-00007

M3 - Article

VL - 18

SP - 1133

EP - 1141

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 15

ER -